Michael Halpin
Chief Operating Officer chez VERICEL CORPORATION
Fortune : 49 367 $ au 31/03/2024
Profil
Michael Halpin is currently the Chief Operating Officer at Vericel Corp.
Prior to his current position, he held the role of Vice President-North American Region Regulatory at Genzyme Corp.
from 2002 to 2017.
He also worked as Vice President-North American Region Regulatory at Sanofi Corp.
Mr. Halpin completed his undergraduate and graduate degrees at the University of Virginia.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
VERICEL CORPORATION
0,00% | 11/03/2024 | 949 ( 0,00% ) | 49 367 $ | 31/03/2024 |
Postes actifs de Michael Halpin
| Sociétés | Poste | Début |
|---|---|---|
| VERICEL CORPORATION | Chief Operating Officer | 15/06/2019 |
Anciens postes connus de Michael Halpin
| Sociétés | Poste | Fin |
|---|---|---|
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | General Counsel | - |
| Sanofi Corp. | Corporate Officer/Principal | - |
Formation de Michael Halpin
| University of Virginia | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| VERICEL CORPORATION | Health Technology |
| Entreprise privées | 2 |
|---|---|
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
| Sanofi Corp. |
